If you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is Viking Therapeutics (NASDAQ: VKTX). Although the business isn't generating any revenue yet, there's loads of opportunity for the company in the long run. ...
motleyfoolusx:vktx
Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown, equities will fall, and many won't deliver anything approaching decent returns for years after. So it's important ...
motleyfoolusx:vktxusx:rxrx
Up 260% so far this year, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity thanks to its increasingly promising therapies in development to treat obesity. But as wise investors know, buying a small biotech stock immediately after it has significantly gained in value can be a especially ...
motleyfoolusx:vktx
If you go to California's Redwood National Park, you can see the world's tallest tree -- a redwood called Hyperion that's over 380 feet tall. Like every other tree, though, Hyperion started as a small seed. Stocks can be like this, beginning small but growing to a giant size over time. Three Motley Fool ...
motleyfoolusx:altusx:vktxusx:axsm
Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster -- or better yet, one that becomes a blockbuster drug -- that can be a game changer, and lead to a soaring ...
motleyfoolusx:vktx
Viking Therapeutics (NASDAQ: VKTX) has been one of the few bright spots in the healthcare sector this year. The biotech's shares have stormed higher by almost 300% year to date on the back of its midstage weight-loss candidate, VK2735. The lowdown is that VK2735 could be a top three weight-loss medication ...
motleyfoolusx:vktx
Viking Therapeutics (NASDAQ: VKTX) isn't a household name, but if its plans to commercialize a powerful anti-obesity medicine come to fruition, it may well become one. Though it has yet to commercialize a drug, unlike its primary big pharma competitors, the data about the performance of its lead program ...
motleyfoolusx:vktx
Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled the biotech's stock to a staggering 714% surge since the completion of the drug's Phase 1 trial on March ...
motleyfoolusx:vktx
Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller biotechs to see their stock prices skyrocket relatively quickly, but many eventually give up most, if not ...
motleyfoolusx:vktx
Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics ...
motleyfoolusx:llyusx:vktxusx:crsp
